hotspot -WSS

hotspot

author：comprehensive 2025-10-04 11:35:59 - browse：8

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： The unintended consequences of overturning Roe v. Wade

WSS

Patients, doctors press FTC to beef up hospital merger scrutiny

Patients, doctors press FTC to beef up hospital merger scrutiny

Why the drug industry's warnings on the IRA's impact fall short

Why the quest to eradicate polio has stumbled

FDA panel to weigh safety of artificial wombs for preterm births

In 'major milestone,' FDA approves first cell therapy for solid tumors

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

White House Covid adviser calls on docs to combat misinformation

How one medical school became remarkably diverse

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

United colonoscopy coverage change 'may cost lives,' doctors say

People with substance use disorder deserve online privacy

How one medical school became remarkably diverse

How the messy conversation about Dolly changed bioethics

At least 13 dead in Texas as scorching temps continue

People with substance use disorder deserve online privacy

focus

Grad students accuse University of California of wage theft

Why the quest to eradicate polio has stumbled

A new drug could help frostbite victims avoid its ravages

Akili changes sales model for its ADHD video game treatment

White House Covid adviser calls on docs to combat misinformation

FDA warns medical device makers about rise in fabricated data

entertainment

hotspot

hotspot

entertainment